Accuracy of serological testing for SARS‐CoV‐2 antibodies: First results of a large mixed‐method evaluation study

Serological immunoassays that can identify protective immunity against SARS‐CoV‐2 are needed to adapt quarantine measures, assess vaccination responses, and evaluate donor plasma. To date, however, the utility of such immunoassays remains unclear. In a mixed‐design evaluation study, we compared the diagnostic accuracy of serological immunoassays that are based on various SARS‐CoV‐2 proteins and assessed the neutralizing activity of antibodies in patient sera.

[1]  Y. Yazdanpanah,et al.  A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations , 2020, Science Translational Medicine.

[2]  Mark S. Anderson,et al.  Test performance evaluation of SARS-CoV-2 serological assays , 2020, Nature biotechnology.

[3]  I. Martín-Antoniano,et al.  Cross‐sectional pilot study exploring the feasibility of a rapid SARS‐CoV‐2 immunization test in health and nonhealthcare workers , 2020, Allergy.

[4]  R. Guieu,et al.  Blood myeloperoxidase‐DNA, a biomarker of early response to SARS‐CoV‐2 infection? , 2020, Allergy.

[5]  A. Paller,et al.  SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age , 2020, Allergy.

[6]  P. Schmid‐Grendelmeier,et al.  SARS‐CoV‐2, COVID‐19, skin and immunology – What do we know so far? , 2020, Allergy.

[7]  K. Hoffmann‐Sommergruber,et al.  Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI) , 2020, Allergy.

[8]  S. Lee,et al.  Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients , 2020, Emerging infectious diseases.

[9]  J. Bousquet,et al.  A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2 , 2020, Allergy.

[10]  Kari C. Nadeau,et al.  Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors , 2020, Allergy.

[11]  M. Drayson,et al.  SARS-CoV-2 seroconversion in health care workers , 2020, medRxiv.

[12]  Florian Krammer,et al.  Serology assays to manage COVID-19 , 2020, Science.

[13]  R. König,et al.  SARS‐CoV‐2 immunogenicity at the crossroads , 2020, Allergy.

[14]  Cezmi A Akdis,et al.  Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19 , 2020, Allergy.

[15]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[16]  C. Akdis,et al.  Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status , 2020, Allergy.

[17]  S. Yerly,et al.  Validation of a commercially available SARS-CoV-2 serological immunoassay , 2020, Clinical Microbiology and Infection.

[18]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[19]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[20]  Mayda Gursel,et al.  Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic? , 2020, Allergy.

[21]  C. Taddei,et al.  Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience , 2020, Journal of medical virology.

[22]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[23]  Po Ying Chia,et al.  Connecting clusters of COVID-19: an epidemiological and serological investigation , 2020, The Lancet Infectious Diseases.

[24]  S. Hegde,et al.  The important role of serology for COVID-19 control , 2020, The Lancet Infectious Diseases.

[25]  N. Watkins,et al.  Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays , 2020, medRxiv.

[26]  Ruth Gilbert,et al.  Universal weekly testing as the UK COVID-19 lockdown exit strategy , 2020, The Lancet.

[27]  Xiangxi Wang,et al.  Rapid development of an inactivated vaccine for SARS-CoV-2 , 2020, bioRxiv.

[28]  C. Boesecke,et al.  Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity , 2020, Public Health.

[29]  Kaijun Jiang,et al.  SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.

[30]  C. Akdis,et al.  Distinct characteristics of COVID‐19 patients with initial rRT‐PCR‐positive and rRT‐PCR‐negative results for SARS‐CoV‐2 , 2020, Allergy.

[31]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[32]  Jonathan E. Schmitz,et al.  Laboratory Diagnosis of COVID-19: Current Issues and Challenges , 2020, Journal of Clinical Microbiology.

[33]  Shangen Zheng,et al.  Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 , 2020, Journal of Clinical Microbiology.

[34]  S. Zheng,et al.  Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2 , 2020, medRxiv.

[35]  Pu Liao,et al.  Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice , 2020, medRxiv.

[36]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[37]  H. Gao,et al.  Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2 , 2020, bioRxiv.

[38]  Lei Liu,et al.  A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients , 2020, Microbes and Infection.

[39]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[40]  S. Blomqvist,et al.  Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[41]  Zheng Zhao,et al.  Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures , 2020, The Lancet.

[42]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[43]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[44]  A. Leichtle,et al.  Rapid Centrifugation in the Routine Hemostasis Laboratory , 2019, Thrombosis and Haemostasis.

[45]  Shuping Zhao,et al.  STARD , 2018, Medicine.

[46]  Jérémie F. Cohen,et al.  STARD 2015: updated reporting guidelines for all diagnostic accuracy studies. , 2016, Annals of translational medicine.

[47]  Muhammad Sajid,et al.  Designs, formats and applications of lateral flow assay: A literature review , 2015 .

[48]  B. Fielding,et al.  The Coronavirus Nucleocapsid Is a Multifunctional Protein , 2014, Viruses.

[49]  B. Bosch,et al.  The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.

[50]  Jonathan E. Schmitz,et al.  The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges 1 , 2020 .

[51]  C. Selmi,et al.  Experimental evidence on the immunopathogenesis of primary biliary cirrhosis , 2010, Cellular and Molecular Immunology.